Iclusig Deaths Won't Stall FDA's Speedier Drug Approvals
The jarring death toll linked to leukemia drug Iclusig will force the U.S. Food and Drug Administration to revisit the science that won the product accelerated approval, but a growing willingness...To view the full article, register now.
Already a subscriber? Click here to view full article